HNWAG
CLDX icon

High Net Worth Advisory Group’s Celldex Therapeutics CLDX Stock Holding History

High Net Worth Advisory Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$44.6K – 259
2022
Q4 		$44.6K Hold
1,000
– – 0.02% 345
2022
Q3 		$28K Sell
1,000
-1,000
-50% -$30.7K 0.01% 410
2022
Q2 		$54K Hold
2,000
– – 0.02% 308
2022
Q1 		$68K Hold
2,000
– – 0.02% 299
2021
Q4 		$77K Buy
+2,000
New +$87.2K 0.03% 292

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

High Net Worth Advisory Group's CLDX Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 1,000 shares — an estimated $44.6K sold.

High Net Worth Advisory Group first reported a position in CLDX in Q4 2021 and held it in 5 quarters. The position peaked at $77K in Q4 2021. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • High Net Worth Advisory Group reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Celldex Therapeutics shares in Q1 2023, an estimated $44.6K.
  • High Net Worth Advisory Group first reported a position in Celldex Therapeutics in Q4 2021 and held it in 5 quarters.
  • High Net Worth Advisory Group's Celldex Therapeutics position peaked at $77K in Q4 2021.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.